EGFR-TKIs获得性耐药机制及耐药后治疗方案探讨  

Probe on EGFR-TKIs acquired-drug resistance and treatment after acquired-drug resistance

作　　者：杜梦楠[1,2] 张莹 杨兰兰[1] 齐晓玉 DU Mengnan;ZHANG Ying;YANG Lanlan;QI Xiaoyu(Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300000, China)

机构地区：[1]天津中医药大学,天津300193 [2]天津中医药大学第一附属医院,天津300000

出　　处：《药物评价研究》2018年第5期924-928,共5页Drug Evaluation Research

基　　金：天津市高等学校科技发展基金计划项目(20110223)

摘　　要：以表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)为代表的分子靶向药物治疗肿瘤,可明显延长非小细胞肺癌患者的无进展生存期和改善患者的生活质量,但面临耐药以及耐药后如何继续治疗等问题。阐述EGFR-TKI的作用机制和获得性耐药机制,分别对耐药后快速进展、缓慢进展和局部进展3种进展情况提出了诊疗意见,以期为改善耐药、加强疗效提供借鉴。On the behalf of molecule targeted drugs, epidermal growth factor receptor tyrosine kinase inhibitors（EGFR-TKI） can prolong the progression free survival and improve life quality of non-small-cell lung cancer patients, yet the drug-resisitance and treatment after can not be ignored. State the mechanism of EGFR-TKI and acquired drug-resistance, provide treatment opinions for rapid progress, slow progress and local advancement, meanwhile achieving the target of reversing drug-resistance and strengthening curative effect.

关 键 词：表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI) 非小细胞肺癌 靶向药物 耐药 靶向治疗 

分 类 号：R73-051[医药卫生—肿瘤]